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Depression is common in end-stage renal disease and is
associated with poor quality of life and higher mortality;
however, little is known about depressive affect in earlier
stages of chronic kidney disease. To measure this in a risk
group burdened with hypertension and kidney disease, we
conducted a cross-sectional analysis of individuals at
enrollment in the African American Study of Kidney Disease
and Hypertension Cohort Study. Depressive affect was
assessed by the Beck Depression Inventory II and quality of
life by the Medical Outcomes Study-Short Form and the
Satisfaction with Life Scale. Beck Depression scores over 14
were deemed consistent with an increased depressive affect
and linear regression analysis was used to identify factors
associated with these scores. Among 628 subjects, 166 had
scores over 14 but only 34 were prescribed antidepressants.
The mean Beck Depression score of 11.0 varied with the
estimated glomerular filtration rate (eGFR) from 10.7 (eGFR
50–60) to 16.0 (eGFR stage 5); however, there was no
significant independent association between these.
Unemployment, low income, and lower quality and
satisfaction with life scale scores were independently and
significantly associated with a higher Beck Depression score.
Thus, our study shows that an increased depressive affect is
highly prevalent in African Americans with chronic kidney
disease, is infrequently treated with antidepressants, and is
associated with poorer quality of life. Sociodemographic
factors have especially strong associations with this increased
depressive affect. Because this study was conducted in an
African-American cohort, its findings may not be generalized
to other ethnic groups.
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Depression is a common condition among individuals with
end-stage renal disease (ESRD) and increases the risk of
serious adverse health outcomes, including mortality, more
frequent hospitalization, and poorer quality of life.1–11
Between 15 and 30% of ESRD patients either report
symptoms of depression or are clinically diagnosed with this
condition.1–4,12–18 Although the effect of antidepressant
treatment in ESRD is largely unknown, uncontrolled studies
have found possible efficacy.19,20 However, only a small
proportion of ESRD patients with depression are prescribed
antidepressant medications.7,12,16,17
Although numerous studies of depression have been
conducted in people with ESRD, its burden among
individuals with earlier stages of chronic kidney disease
(CKD) and its relationship with kidney function is less well
described.21–25 The reported prevalence of increased depres-
sive affect among patients with CKD before attainment of
ESRD has varied substantially, ranging from approximately
15% to over 50%.21,22,25 Moreover, conflicting conclusions
have been reached regarding a potential relationship between
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the severity of CKD and depression.21–25 These heterogeneous
findings may be a result of shortcomings in study design such
as small sample size and sampling of a single geographic
region.
Hypertension is the second leading cause of ESRD in the
United States and is especially burdensome to African
Americans.26 The African American Study of Kidney Disease
and Hypertension (AASK) cohort study was designed to
identify important risk factors for decline in kidney function
and to improve the understanding of CKD in African
Americans with hypertensive kidney disease.27,28 In this
analysis, we characterized the prevalence of increased
depressive affect and examined its cross-sectional association
with sociodemographic factors, comorbid health conditions,
level of kidney function, and quality of life in the AASK
cohort.
RESULTS
Study participants and baseline BDI-II scores
Among the 628 AASK subjects enrolled in the cohort study,
the mean (±s.d.) baseline Beck Depression Inventory II
(BDI-II) score was 11.0±8.3 (Figure 1). The distribution of
the AASK cohort subjects by strata of baseline BDI-II scores
was as follows: 58% (0–10), 16%(11–14), 15%(15–21), and
11% (421).
Demographic characteristics and baseline BDI-II scores
The mean age of the cohort was approximately 60 years and
38% were females (Table 1). In all, 40% of subjects had not
completed high school, 42% had an annual income of
o$15,000, and 15% were unemployed. The mean estimated
glomerular filtration rate (eGFR) was 43.1±16.1 ml/min per
1.73 m2. Several sociodemographic characteristics differed
among the subjects when the range of BDI-II scores was
considered (Table 1). A significant inverse relationship was
observed between BDI-II scores and unemployment and
annual household incomes of o$15,000 (Po0.05). Partici-
pants with BDI-II scores of421 were three times as likely to
be unemployed (32 vs 10%), and nearly twice as likely to
have an annual household income of o$15,000 (63 vs 34%)
when compared with those with BDI-II scores of 0–10.
Clinical characteristics and baseline BDI-II scores
No consistent or significant trends were observed between
strata of BDI-II scores and prevalence of most selected
comorbid health conditions (Table 2). However, patients
with BDI-II scores of421 were between two and four times
more likely to have a history of stroke or psychiatric problem,
respectively, compared with those with BDI-II scores of 0–10
(Po0.05). eGFR and proteinuria did not vary significantly
across the range of BDI-II scores (P40.05). Medical
Outcomes Study-Short Form-36-Item (MOS-SF-36) Mental
Health Component (MHC) scores, MOS-SF-36 Physical
Health Component (PHC) scores, and Satisfaction with Life
Scale (SWLS) scores decreased significantly with increasing
BDI-II scores (Po0.0001).
Demographic and clinical characteristics by increased
depressive affect and prescription of antidepressants
The mean BDI-II scores varied as follows: 6.9±3.8 for
participants without depressive affect (BDI-II of p14),
21.7±6.4 for those with increased depressive affect (BDI-II
of 414) but without antidepressant medication, and
18.2±11.4 for those prescribed antidepressants (Table 3).
There were a few significant differences in characteristics
between these groups. Compared with participants without
depressive affect, those prescribed antidepressants were
significantly more likely to have a history of current smoking,
unemployment, chronic obstructive pulmonary disease,
psychiatric illness and to be of younger age (Po0.05).
Compared with participants with increased depressive affect,
those prescribed antidepressants differed significantly only in
a greater prevalence of a history of smoking and psychiatric
illness (Po0.05). MOS-SF-36 MHC scores and MOS-SF-36
PHC scores were progressively lower from those without
depressive affect to those with increased depressive affect and
to those prescribed antidepressants (Po0.0001). SWLS
scores were similar among participants with increased
depressive affect and prescribed antidepressants but signifi-
cantly lower compared with those without depressive affect
(Po.0001). eGFR did not vary significantly across these
groups (P40.05). A sensitivity analysis was conducting using
a BDI-II score of X11 as a cutoff for increased depressive
affect and the comparison results for the three groups were
not significantly changed.
Kidney function, baseline BDI-II scores, and prescription of
antidepressants
Mean BDI-II scores and distribution of BDI-II score strata
were similar among subjects with eGFR values of 415 ml/
min per 1.73 m2 (Table 4), but they were higher in subjects
with an eGFR of p15 ml/min per 1.73 m2. Compared with
those with an eGFR of 415 ml/min per 1.73 m2, the mean
BDI-II score (10.7 vs 16.0) and proportion of BDI-II scores of
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Figure 1 |Distribution of Beck Depression Inventory II (BDI)
scores in the African American Study of Kidney Disease and
Hypertension (AASK) cohort at baseline.
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Table 1 | Baseline demographic characteristics by BDI-II scores
Overall (N=628) BDI 0–10 (N=363) BDI 11–14 (N=99) BDI 15–21 (N=95) BDI 421 (N=71)
Variable
% (n) or
mean±(s.d.)
% (n) or
mean±(s.d.)
% (n) or
mean±(s.d.)
% (n) or
mean±(s.d.)
% (n) or
mean±(s.d.) P-value
Age 60.1±10.2 60.5±10.4 60.6±9.35 58.9±11.0 59.1±8.71 0.43
Female 38% (238) 35% (128) 44% (44) 40% (38) 39% (28) 0.37
Education (from trial) 0.15
Not a HS graduate 40% (250) 37% (135) 42% (42) 39% (37) 51% (36)
HS graduate or beyond 60% (377) 63% (228) 58% (57) 61% (58) 49% (34)
Marital status 0.05
Married/married-like relationship 36% (228) 40% (146) 32% (32) 28% (27) 32% (23)
Not married/married-like
Relationship+not living alone 29% (183) 28% (102) 24% (24) 30% (29) 39% (28)
Not married/married-like
Relationship+living alone 34% (216) 31% (114) 43% (43) 41% (39) 28% (20)
Income o0.001
o$15,000 42% (261) 34% (123) 44% (44) 52% (49) 63% (45)
X$15,000 37% (232) 41% (149) 38% (38) 33% (31) 20% (14)
Declined to answer 21% (135) 25% (91) 17% (17) 16% (15) 17% (12)
Health insurance 0.054
Private/HMO/other 30% (191) 32% (115) 37% (37) 23% (22) 24% (17)
Medicaid only 11% (71) 10% (35) 12% (12) 14% (13) 15% (11)
Medicare 29% (184) 28% (103) 25% (25) 27% (26) 42% (30)
None/uninsured 29% (181) 30% (109) 25% (25) 36% (34) 18% (13)
Employment status o0.0001
Employed 37% (232) 42% (153) 41% (41) 25% (24) 20% (14)
Unemployed 15% (94) 10% (37) 12% (12) 23% (22) 32% (23)
Retired 36% (223) 37% (134) 37% (37) 33% (32) 28% (20)
Other 12% (78) 10% (38) 9% (9) 18% (17) 20% (14)
Patient currently exercises 61% (381) 63% (230) 58% (59) 60% (57) 51% (36) 0.22
Smoking status 0.74
Never smoked 40% (252) 42% (151) 39% (39) 42% (40) 31% (22)
Currently smoking 17% (104) 16% (58) 15% (15) 18% (17) 20% (14)
Past smoker 43% (271) 42% (153) 45% (45) 40% (38) 49% (35)
Alcohol use 15% (94) 15% (55) 16% (16) 18% (17) 8% (6) 0.37
Recreational i.v. drug use 0.6% (4) 0.3% (1) 1% (1) 2% (2) 0% (0.0) 0.19
Abbreviations: BDI-II, Beck Depression Inventory II; HMO, health maintenance organization; HS, high school; i.v., intravenous.
Table 2 | Baseline clinical characteristics by BDI-II scores
Overall (N=628) BDI 0–10 (N=363) BDI 11–14 (N=99) BDI 15–21 (N=95) BDI 421 (N=71) P-value
Weight (kg) 92.1±22.4 92.0±21.3 93.0±22.1 91.8±23.0 91.9±27.5 0.98
Body mass index (kg/m2) 31.5±7.12 31.3±6.79 31.8±7.39 31.8±7.25 31.3±8.34 0.89
Systolic BP (mmHg) 135±21.8 134±20.5 137±22.7 139±25.2 133±21.7 0.20
Diastolic BP (mmHg) 80.7±12.1 80.0±11.6 82.0±13.5 81.4±12.0 81.4±12.9 0.41
Serum creatinine (mg/dl) 2.32±1.32 2.28±1.15 2.14±1.04 2.65±2.02 2.31±1.24 0.04
Estimated GFR (ml/min per 1.73m2) 43.1±16.1 43.2±15.8 44.0±14.8 41.1±17.6 43.5±17.0 0.62
Urine protein/creatinine 0.38±0.85 0.34±0.72 0.47±1.08 0.52±1.06 0.31±0.74 0.19
Urine protein/creatinine 40.22 30% (188) 28% (103) 32% (31) 39% (36) 27% (18) 0.24
Serum albumin (g/dl) 4.00±0.33 4.02±0.32 3.95±0.34 3.96±0.33 4.01±0.30 0.17
Hemoglobin (g/dl) 12.7±1.82 12.8±1.86 12.8±1.88 12.5±1.80 12.6±1.55 0.53
History of cardiovascular disease 29% (185) 25% (91) 39% (39) 23% (22) 46% (33) 0.0002
History of stroke 18% (115) 16% (58) 14% (14) 21% (20) 32% (23) 0.006
History of peripheral vascular disease 6% (35) 4% (15) 9% (9) 3% (3) 11% (8) 0.027
History of cancer 6% (36) 6% (23) 4% (4) 6% (6) 4% (3) 0.077
History of asthma or COPD 7% (47) 6% (21) 7% (7) 8% (8) 15% (11) 0.042
Psychiatric problem 4% (23) 1% (5) 4% (4) 7% (7) 10% (7) 0.0008
MOS-SF-36 MHC score 52.4±9.90 56.6±6.60 49.8±9.52 47.7±10.8 40.7±10.1 o0.0001
MOS-SF-36 PHC score 41.1±11.3 43.5±10.7 39.3±11.1 39.3±11.7 34.2±10.3 o0.0001
SWLS score 4.44±1.52 4.94±1.35 4.14±1.37 3.65±1.46 3.32±1.47 o0.0001
Abbreviations: BDI-II, Beck Depression Inventory II; BP, blood pressure; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; MHC, Mental
Health Component; MOS-SF-36, Medical Outcomes Study-Short Form-36-Item; PHC, Physical Health Component; SWLS, Satisfaction with Life Scale.
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414 (22 vs 52%) were greater in subjects with an eGFR of
p15 ml/min per 1.73 m2. However, there was no overall
statistically significant association between BDI-II strata and
levels of eGFR (P40.05).
The overall proportion of study subjects who were
prescribed antidepressant medications was 5.4% and ranged
from 3% in subjects with BDI-II scores between 0 and 10 to
17% in subjects with BDI-II scores of 421. Higher BDI-II
score was significantly associated with a higher likelihood of
prescription of antidepressants (Po0.001). No significant
relationship was observed between prescription of anti-
depressants and levels of eGFR (P40.05).
Independent association of demographic factors with
baseline BDI-II scores
In linear regression analysis, three sociodemographic factors
were significantly and independently associated with BDI-II
scores after adjusting for eGFR (Table 5). Study participants
who currently exercised had lower BDI-II scores (para-
meter¼1.74, s.e.¼ 0.66, P¼ 0.009) compared with sub-
jects who did not exercise. Annual household income of
o$15,000 (referent: household income of X$15,000) and
unemployment (referent: employment) were strongly asso-
ciated with higher BDI-II scores (parameter¼ þ 2.30,
s.e.¼ 0.85, P¼ 0.007 and parameter¼ þ 4.94, s.e.¼ 1.09,
Table 3 | Significant baseline demographic and clinical characteristic differences by depressive affect and prescription of
antidepressant medications
Variable
Depressive
affect absent
(N=447)
Depressive
affect present
(N=147)
Prescribed
antidepressant
(N=34)
Absent depressive
affect vs present
depressive affect
(P-value)
Absent depressive
affect vs
antidepressant
(P-value)
Present depressive
affect vs
antidepressant
(P-value)
BDI-II score 6.9±3.8 21.7±6.4 18.2±11.4 o0.001 o0.001 0.078
Age 60.6±10.2 59.6±10.2 56.2±9.4 0.322 0.044 0.148
Income 0.001 0.248 0.609
X$15,000 40% (179) 28% (41) 35% (12)
o$15,000 36% (162) 55% (81) 53% (18)
Declined to answer 24% (106) 17 % (25) 12% (4)
Employment status o0.0001 o0.0014 0.238
Employed 42% (187) 25% (36) 27% (9)
Unemployed 11% (47) 23% (34) 38% (13)
Retired 37% (165) 35% (51) 21% (7)
Other 11% (47) 18% (26) 15% (5)
Smoking status 0.811 0.0013 0.0030
Never smoked 42% (185) 39% (57) 29% (10)
Currently smoking 15% (67) 15% (22) 44% (15)
Past smoker 44% (194) 46% (68) 27% (9)
History of psychiatric problem 1% (6) 5% (7) 29% (10) 0.022 o0.001 o0.001
History of asthma or COPD 6% (25) 10% (14) 24% (8) 0.123 0.003 0.076
MOS-SF-36 MHC score 55.4±7.46 46.0±10.7 39.9±12.2 o0.001 o0.001 o0.001
MOS-SF-36 PHC score 42.7±10.8 37.9±11.0 34.9±13.4 o0.001 o0.001 0.155
SWLS score 4.77±1.39 3.57±1.46 3.76±1.72 o0.001 o0.001 0.490
Estimated GFR
(ml/min per 1.73m2)
43.4±15.6 42.7±17.0 39.8±18.1 0.692 0.630 0.692
Abbreviations: BDI-II, Beck Depression Inventory II; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; MHC, Mental Health Component;
MOS-SF-36, Medical Outcomes Study-Short Form-36-Item; PHC, Physical Health Component; SWLS, Satisfaction with Life Scale.
Table 4 | BDI-II scores by baseline eGFRa
Variable
Overall
(N=622)
eGFR p15
(N=21)
eGFR 16–30
(N=115)
eGFR 30–40
(N=113)
eGFR 40–50
(N=132)
eGFR 50–60
(N=136)
eGFR 460
(N=105)
BDI score
(mean±s.d.)
11.0±8.27 16.0±12.4 10.4±7.32 11.0±8.45 11.1±8.82 10.7±7.93 10.8±7.49
BDI groups (% (n))
0–10 58% (362) 38% (8) 63% (73) 55% (62) 56% (74) 64% (87) 55% (58)
11–14 16% (97) 10% (2) 12% (14) 18% (20) 19% (25) 14% (19) 16% (17)
15–21 15% (94) 33% (7) 17% (19) 14% (16) 13% (17) 14% (19) 15% (16)
421 11% (69) 19% (4) 8% (9) 13% (15) 12% (16) 8% (11) 13% (14)
Abbreviations: BDI-II, Beck Depression Inventory II; eGFR, estimated glomerular filtration rate.
aSix patients with missing baseline eGFR were excluded.
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Po0.0001, respectively). Sensitivity analyses were performed
excluding patients with baseline antidepressant medication
use and the resulting findings were not significantly changed.
Independent association of clinical factors with baseline
BDI-II scores
eGFR did not have a significant independent association with
BDI-II scores upon linear regression analysis incorporating
other clinical factors (P¼ 0.75; Table 6). History of stroke
was independently associated with higher BDI-II scores
(parameter¼ þ 1.97, s.e.¼ 0.68, P¼ 0.004). Lower MOS-
SF-36 MHC scores (parameter¼0.39, s.e.¼ 0.03,
Pp0.0001), PHC scores (parameter¼0.14, s.e.¼ 0.03,
Po0.0001), and SWLS scores (parameter¼0.94,
s.e.¼ 0.20, Po0.0001) were all associated with higher BDI-
II scores. If MOS-SF-36 MHC, PHC, and SWLS scores are
excluded from this regression, history of psychiatric problem
(parameter¼ þ 8.06, s.e.¼ 1.73, Po0.0001) and cardiovas-
cular disease (parameter¼ þ 1.70, s.e.¼ 0.72, P¼ 0.02) also
become significantly associated with higher BDI-II scores.
Sensitivity analyses were performed excluding patients with
baseline antidepressant medication use and the resulting
findings were not significantly changed.
DISCUSSION
We observed a prevalence of increased depressive affect of at
least 26% among a large cohort of African Americans with
hypertensive CKD, based on a BDI-II score of 414. An
additional 2% of subjects without increased depressive affect
as assessed by the BDI-II were prescribed antidepressant
medications, suggesting that nearly one-third of the AASK
cohort study participants have clinically significant depressive
affect. The prevalence of increased depressive affect in this
cohort of African Americans with CKD is substantially
elevated compared with that in the general healthy popula-
tion. In a study of over 9000 non-medically ill adults across
the United States, the NCS-R (National Comorbidity Survey
Replication survey, the 12-month period prevalence of a
major depressive disorder was found to be 6.6%.29 This
contrast is even more striking considering that we used a
conservative BDI threshold to define clinically significant
depressive affect. If a less conservative BDI cutoff of X11 is
Table 5 | Association of baseline sociodemographic factors and eGFR with BDI-II scorea
Variable Parameter estimate Standard error P-value
Age (per 10 years) 0.66 0.42 0.12
Female 0.21 0.70 0.76
Less than HS degree 1.05 0.73 0.15
Married/married-like relationship vs not married/married-like relationship+living alone 0.99 0.83 0.23
Not married/married-like relationship+not living alone vs not married/married-like
relationship+living alone
0.45 0.82 0.59
o$15,000 vs X$15,000 2.30 0.85 0.007
Declined to answer vs X$15,000 0.83 0.89 0.35
Private/HMO/other vs Medicare 0.75 1.04 0.47
Medicaid only vs Medicare 0.28 1.16 0.81
None/uninsured vs Medicare 0.09 0.90 0.92
Retired vs employed 1.79 0.93 0.05
Unemployed vs employed 4.94 1.09 o0.0001
Other vs employed 3.80 1.15 0.001
Patient currently exercises 1.74 0.66 0.009
Current smokers vs never smoked 0.67 0.98 0.49
Past smokers vs never smoked 1.00 0.72 0.17
Alcohol use 0.08 0.90 0.93
Recreational i.v. drug use 2.36 4.03 0.56
Estimated GFR (per 10ml/min per 1.73m2) 0.05 0.20 0.82
Abbreviations: BDI-II, Beck Depression Inventory II; eGFR, estimated glomerular filtration rate; HMO, health maintenance organization; HS, high school; i.v., intravenous.
aRegression coefficients shown are from multiple regression jointly relating BDI score to each of the listed predictor variables. The regression coefficients indicate the mean
difference in the BDI score associated with the indicated characteristic for dichotomous predictor variables, or a one-unit increase in quantitative predictor variables.
Table 6 | Association of baseline comorbidities, functional
health status, and eGFR with BDI-II scorea
Variable
Parameter
estimate
Standard
error P-value
Age (per 10 years) 0.33 0.27 0.22
Female 0.35 0.54 0.52
History of cancer 1.63 1.16 0.1598
History of stroke 1.97 0.68 0.004
History of peripheral vascular
disease
0.35 1.17 0.77
History of psychiatric problem 1.78 1.43 0.21
History of asthma or COPD 0.44 1.01 0.66
History of cardiovascular disease 0.54 0.58 0.36
MOS-SF-36 MHC score 0.39 0.03 o0.0001
MOS-SF-36 PHC score 0.14 0.03 o0.0001
SWLS score 0.94 0.20 o0.0001
Estimated GFR (per 10ml/min per
1.73m2)
0.05 0.16 0.75
Abbreviations: BDI-II, Beck Depression Inventory II; COPD, chronic obstructive
pulmonary disease; eGFR, estimated glomerular filtration rate; MHC, Mental Health
Component; MOS-SF-36, Medical Outcomes Study-Short Form-36-Item; PHC,
Physical Health Component; SWLS, Satisfaction with Life Scale.
aRegression coefficients shown are from multiple regression jointly relating BDI
score to each of the listed predictor variables. The regression coefficients indicate
the mean difference in the BDI score associated with the indicated characteristic for
dichotomous predictor variables, or a one-unit increase in quantitative predictor
variables.
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used, as suggested by a recent study,30 over 4 in 10
participants of the AASK cohort have increased depressive
affect. It is important to underscore the applicability of these
observations. The AASK cohort was recruited from over 20
clinical centers in cities across the United States and is a large
diverse sample of African Americans with hypertensive
CKD.28 Findings from the AASK cohort are well recognized
to be inherently generalizable to African Americans with
CKD, who constitute a vulnerable population subject to
health disparities and overrepresented in the CKD and ESRD
community.27,28,31–33
To our knowledge, this report is the first large detailed
epidemiologic study of depression in people with earlier
stages of CKD before the onset of chronic dialysis. Previous
small studies have reported a wide range of prevalent
depressive symptoms in patients with CKD, which may be
attributed to differences in study populations, definitions and
stage of CKD, comorbid conditions, and instruments used to
assess and define depressive affect.21–25 Although only 17% of
subjects with moderate CKD in the Heart and Soul Study had
depressive symptoms, the mean BDI score in a small group of
outpatients with severe CKD from Iowa was quite elevated at
12.8, suggestive of mild depressive affect.22,34 More similar to
the urban African-American cohort of this study, two
analyses of outpatients with moderate-to-severe CKD in
Washington DC found substantially lower mean BDI scores
that ranged from 7.4 to 8.23,24 However, these two previous
works were single-center studies without published details
regarding socioeconomic data. Therefore, their representa-
tiveness is unclear and fully accounting for their disconcor-
dance from these present results is not possible.23,24 A recent
study conducted at a Veterans Affairs Medical Center in Texas
suggests that 21% of male veterans with CKD stages 2 to 5
have an episode of clinically diagnosed major depression.25
The prevalence of increased depressive affect in the AASK
cohort was similar, using respective criteria, to that observed
in chronic ESRD patients undergoing maintenance dialysis,
in which the prevalence of increased depressive affect or the
clinical diagnosis of depression has generally ranged from
15 to 30%.1–4,12–18 Previous studies of predominately African-
American chronic hemodialysis patients have found mean
BDI scores between 11 and 13.5,8,18 The prevalence of
increased depressive affect among the AASK cohort did not
vary substantially by level of kidney function except
among people with very low kidney function (eGFR of
o15 ml/min per m2), in which increased depressive affect
was noticeably the highest. Regression analysis supported this
observation by finding eGFR not to be independently
associated with BDI-II score. Similar to findings reported
in this study, although previous studies have reported no
overall significant correlation between depression and eGFR,
noteworthy increases in depressive symptoms were found
with very severe decrements in kidney function.21,23–25
Although inconsistencies in the literature exist because
of differences in the timing of depression assessments
and unmeasured qualitative factors,5,7,9,34 previous analyses
of patients initiating hemodialysis have revealed rates of
depression to be much higher than that in their chronic
hemodialysis counterparts.6,7,10 Major lifestyle and psycho-
logical adjustments, and multiple losses that occur during the
transition from severe CKD to ESRD requiring dialysis, may
account for these observations.7,16,35,36 Importantly, only 4%
of the AASK cohort had an eGFR of o15 ml/min per m2;
therefore, our ability to assess and interpret the relationship
between depressive affect and this very low level of eGFR is
limited. Furthermore, the current understanding of the
relationship between loss of kidney function and develop-
ment of depression is severely limited by the lack of
longitudinal studies.
Our findings confirm previous concerns regarding under-
treatment of depression in patients with CKD.7 Overall,
approximately 5% of AASK study subjects were prescribed
antidepressants, including only 12% with increased depres-
sive affect. In previous studies of chronic hemodialysis
patients with depression, 15 to 50% of such individuals were
prescribed antidepressants.6,7,14,17 Treatment of depression
has been noted to be especially poor in African Amer-
icans.35,37,38 In a study of urban African Americans on
chronic hemodialysis, only 13% of depressed patients were
treated by a mental health provider and only 5% were
prescribed antidepressant medications.18 Although the AASK
study is limited by not possessing data regarding non-
pharmacologic depression treatments, our findings raise
further concerns regarding the effectiveness of current
depression management. Even among the small number of
AASK participants prescribed antidepressant medications,
average BDI-II scores remained quite elevated. Considering
the negative health outcomes associated with depression and
the potential efficacy of antidepressants in ESRD, greater
scrutiny should be directed toward optimizing care for
depression in CKD patients.1,2,4–6,12,16,18,20
We found strong independent relationships between lower
income, unemployment, and a higher likelihood of increased
depressive affect in the AASK cohort. Adverse socioeconomic
factors are well known to have important associations with
depression.1,17,29,35 In NCS-R survey, unemployment and
poverty were two of the most significant correlates for major
depressive disorder.29 However, in contrast to some previous
works, this present study, despite its extremely detailed
participant data, found relatively few demographic and
clinical factors, such as age, gender, or comorbid illness,
to be significantly associated with increased depressive
affect.1,2,17,19 It is important to underscore that the intricate
relationship between depression and chronic illness is not
fully understood.6,13,16,35,39
Nonetheless, these findings suggest that increased depres-
sive affect may be an occult condition in this high-risk
population; therefore, clinicians must be careful to elicit
indirect evidence of depression in this population. The
presence of worsening somatic symptoms (for example,
fatigue and anorexia) without substantial deterioration in
kidney function, verbal cues (for example, loss of interest and
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indecisiveness), or nonverbal signs (for example, changes in
posture or speech pattern) may be markers of depression.40
Furthermore, clinicians should strongly consider routinely
asking open-ended questions regarding how African-
American patients with CKD are feeling to motivate patients
to disclose and clarify symptoms as well as to foster the
intimacy of the patient–physician relationship, which may
increase the detection of depression.40
Finally, these findings raise the issue of formal screening
for depression in African Americans with CKD. Screening
for depression in general medical populations remains con-
troversial because of conflicting data regarding its effective-
ness in improving the care and outcomes of depressed
patients.12,41 Although depression seems to be especially
common in African Americans with CKD and negatively
affects quality of life, its effect on other medical outcomes is
unknown. Further studies are needed to delineate the clinical
sequelae of depression and to properly assess the utility of
screening in this vulnerable patient population.
There are limitations to this study. First, although the BDI
is a reliable and accurate tool for identifying depression in
ESRD, it has been less well analyzed in CKD.21,23,24,30 We
stressed that this study assessed the extent of increased
depressive affect rather than a clinical diagnosis of depres-
sion.12,16,36 Moreover, previous concerns about the perfor-
mance of the BDI were chiefly focused on the
misclassification of uremic symptoms as somatic symptoms
of depression,4–5,12,14,16,21,35 which is less likely in a popula-
tion with earlier stage CKD before ESRD. Second, we assessed
depressive affect only at baseline in the AASK cohort and
used a cross-sectional study design. The directionality of
associations between depressive affect and other factors
cannot be inferred, and these relationships may evolve over
time. Third, information regarding important qualifying
variables, such as illness intrusiveness and stressful life events,
was not available; therefore, we are limited in making
psychological inferences.42 Fourth, some content overlap
does exist between the BDI-II and the SF-36, and this
measurement redundancy may account for part of the
observed association between quality of life and increased
depressive affect.43 Last, approximately 9% of the AASK
study cohort (63 subjects) did not complete a BDI-II
questionnaire at enrollment and were excluded from this
analysis. However, it is unlikely that their inclusion would
substantially alter our findings because important charac-
teristics among excluded and included subjects were not
significantly different.
In conclusion, increased depressive affect afflicts nearly
one-third of African Americans with CKD, negatively affects
their quality of life, and is rarely treated with pharmacologic
therapy. Clinicians caring for African Americans with CKD
should remain vigilant for the presence of occult depression
in their patients. Current evidence does not warrant screen-
ing for depression in African Americans with CKD. However,
studies are needed to ascertain the clinical consequences of
depression in patients with CKD and to further examine the
potential worsening of depressive symptoms in patients near
ESRD requiring renal replacement therapy, which will inform
the utility of screening. Moreover, clinical trials should be
initiated to evaluate the role of antidepressant treatment
strategies in this population.
MATERIALS AND METHODS
Study design and sample
We conducted a cross-sectional analysis of depressive affect in
subjects at their time of entry (that is, baseline) into the AASK
cohort study. The AASK cohort study was a multicenter prospective
study of people with hypertensive CKD whose hypertension was
managed with a recommended blood pressure goal (o130/
80 mm Hg) and angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker. The AASK cohort study enrolled only
subjects who had previously participated in the AASK clinical trial.
Details of both of these studies have been published previously.27–28
All subjects who were alive at the completion of the clinical trial and
had not begun dialysis therapy or received a kidney transplant were
eligible to enroll in the cohort study. Out of 764 eligible subjects
from the clinical trial who had not begun dialysis therapy or received
a kidney transplant, 691 subjects were enrolled in 2002 and followed
through 2007, and 628 subjects completed a BDI-II questionnaire at
enrollment. Major eligibility criteria for the clinical trial included
self-identified African-American race, ages 18 to 70 years, an
iothalamate measured GFR between 20 and 65 ml/min per 1.73 m2,
and no apparent cause of CKD other than hypertension.28 The study
was approved by the institutional review boards of the participating
centers. All study participants provided written informed consent.
Variables and data sources
The BDI-II was administered as a self-completed questionnaire to all
AASK participants at their baseline visit. The BDI-II is an adaptation
of the Beck Depression Inventory, which is a widely used validated
instrument to assess depressive affect.13–15,44 Scores for each of the
21 items range from 0 to 3 with a higher score representing a greater
problem. The total score range is 0–63, in which a score of o10 is
absence of depression, and scores of 10–15, 16–23, and X24 are
considered mild, moderate, and severe depression, respectively, in
the general non-medically ill population.45 Several studies have
shown that BDI scores of414 are accurate at diagnosing depression
among patients with ESRD.13–15 The BDI has been used less
frequently to evaluate depression in individuals with earlier stages
of CKD.21,23,24 Only one study, which focused on a small male veteran
population, has evaluated the BDI in patients with CKD, finding that
a BDI score ofX11 was the best cutoff point for a major depression
episode.30 Therefore, although we evaluated strata of BDI scores, we
adopted the higher more stringent BDI threshold of 414 to define
significantly increased depressive affect in AASK participants.
Demographic variables (for example, age, gender, education,
marital status, insurance, annual household income, employment
status, current exercise, and smoking/alcohol/drug use) were self-
reported. Comorbid health conditions (for example, cancer, stroke,
cardiovascular disease, peripheral vascular disease, asthma or
chronic obstructive pulmonary disease, and psychiatric problem)
were self-reported and identified by a review of medical records.
Cardiovascular disease included any of the following: coronary
artery disease, heart failure or diastolic dysfunction, left ventricular
hypertrophy, heart rhythm, or conduction problem. Prescription
records of AASK participants were reviewed at baseline and
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medications designated as antidepressants were independently
confirmed by three clinicians. Blood pressure was measured in a
standardized manner by trained, certified observers using the Tycos
Classic Handheld Aneroid device (Skaneateles Falls, NY, USA).
Three blood pressure measurements were obtained in the seated
position and one measurement was obtained in the standing
position and then averaged for a reported value. For each subject,
urine protein/creatinine ratio was measured at baseline as well as
eGFR (ml/min per 1.73 m2), which was calculated using an average
of serum creatinine values with the AASK study equation obtained
within the first 3 months after participant enrollment.46 Quality-of-
Life questionnaire instruments administered included the MOS-SF-
36 and the SWLS.47,48 As described in detail elsewhere, the MOS-SF-
36 consists of 36 items that cover eight domains whose scores are
aggregated into a PHC score and a MHC score.49 These component
scores are normalized to the US population, with a mean of 50 and
an s.d. of 10.50 Higher scores are indicative of better quality of life
than lower scores. The SWLS is a five-item scale dealing with ideal
life, conditions of life, and satisfaction with present and past life that
has a satisfaction rating of 1 to 7 (low to high) for each item.48 The
SWLS has reported good reliability, correlation with other subjective
well-being scales, and has been used in previous studies, including
among patients with CKD.8,9,23,24,48
Statistical analyses
Patient characteristics at baseline were described overall, in four BDI-
II strata (0–10, 11–14, 15–21, and421), and by presence of increased
depressive affect (BDI of 414) or antidepressant medications using
mean±s.d. for quantitative variables and frequencies and percen-
tages for categorical variables. Bivariate analyses involving chi-square
tests and analysis of variance were used as appropriate to assess
differences in patient characteristics among the four BDI-II strata. To
assess the relationship between BDI-II scores and kidney function,
both mean BDI-II scores and BDI-II strata frequency were compared
by levels of eGFR using analysis of variance and Mantel–Haenzel
tests, respectively. Stepdown Bonferroni adjustment was used when
performing pairwise comparisons among subjects with increased
depressive affect (BDI of 414) or without depressive affect (BDI of
p14) or with antidepressant medications.
Multivariable linear regression analysis was used to evaluate the
cross-sectional relationship between baseline BDI-II scores (con-
tinuous variable) and other baseline patient characteristics. Separate
multivariable models were used to examine the relationship between
(1) BDI-II scores and sociodemographic factors, and (2) BDI-II
scores and comorbid conditions, including kidney function (eGFR),
and quality of life. All statistical analyses were conducted with SAS,
version 9.1 (Cary, NC, USA).
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